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P¼0.0027).
Conclusion: Preoperative proteinuria could help stratify patients accord-
ing to the risk of renal function exacerbation.
IPD04:
TUMOR CONTACT SURFACE AREA IS ASSOCIATED WITH VOLUME LOSS
AND FUNCTIONAL DECLINE AFTER PARTIAL NEPHRECTOMY
Yu-De Wang, Chao-Hsiang Chang, Chi-Ping Huang, Hsi-Chin Wu, Che-Rei
Yang, Guang-Heng Chen, Po-Fan Hsieh. Department of Urology, China
Medical University Hospital, Taichung, Taiwan
Purpose: We propose a formula of calculate-based contact surface area
(CSA). We examined the correlation of contact surface area and renal
volume loss and the predictability for renal function after partial
nephrectomy.
Materials and Methods: We conducted a retrospective study in patients
who underwent partial nephrectomy between January 2012 and
December 2014. Based on abdominopelvic CT and MRI, we calculated the
contact surface areawith the formula “2* p *Radius*Depth”; while resected
and ischemic volume (RAIV) was determined by the equation”
[2w^2+3w(r+d)+6rd]*w*p)/3”. We evaluated the correlation between CSA,
RAIV and perioperative parameters. And we comparatively analyzed the
ability of CSA and RAIV to predict the reduction in renal function.
Results: There were 35, 26, and 45 patients receiving OPN, LPN, RPN
respectively. The mean±SD contact surface area was 30.7±26.1 cm2, and
and the mean±SD RAIV was 19.1±14.4 cm3. On Spearman correlation
analysis we found that CSA and RAIV were highly correlated (coefﬁcient:
0.99, p<0.001). In univariate analysis, BMI (p¼0.02), EBL (p¼0.001), RAIV
(p<0.001), and CSA (p<0.001) signiﬁcantly affected postoperative renal
function. In ROC curve analysis, both CSA and RAIV have good ability to
predict more than 10% change of estimated glomerular ﬁltration rate (AUC:
0.86 vs. 0.87). There is no signiﬁcant difference in AUC between CSA and
RAIV. The area difference in PCE10 was 0.002 (p¼0.51)
Conclusion: In our study, CSA and RAIV were correlated with several
perioperative outcomes and affected post-operative renal function. The
ability to predict post-operative renal function between CSA and RAIV was
nearly identical. Since CSA was simpler to use, and may possess less
interobserver variability in comparisonwith RAIV, we believe that CSA can
represent renal parenchymal loss.
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IPD05:
CHARACTERISTICS OF EARLY-ONSET HEMATOTOXICITY OF SUNITINIB
IN JAPANESE PATIENTS WITH RENAL CELL CARCINOMA
Renpei Kato, Yoichiro Kato, Tomohiko Matsuura, Mitsugu Kanehira, Ryo
Takata, Wataru Obara. Department of Urology, Iwate Medical University
School of Medicine, Morioka, Japan
Purpose: To identify the characteristics of early-onset hematotoxicity of
sunitinib in Japanese renal cell carcinoma (RCC) patients.
Material and Methods: Seventy-nine patients were treated with sunitinib
as 6-week cycles of “4-week on 2-week off” schedule. To evaluate early-
onset hematotoxicity, we compared patients with dose reduction during
the ﬁrst cycle (dose-reduced group, n¼57) and those who maintained the
initial dose (dose-maintained group, n¼22). ABCG2 and ﬂt-3 genotypes
were analyzed for association between hematotoxicity and reported gene
polymorphisms.
Results: Mean relative dose intensity (RDI) was similar in two groups
during the ﬁrst two weeks of dosing in the ﬁrst cycle, but was signiﬁcantly
lower in dose-reduced group during the last twoweeks. Lymphocytopenia,
thrombocytopenia, and increased aspartate aminotransferase were
observed in dose-reduced group within the ﬁrst two weeks. Genetic
analysis indicated signiﬁcantly higher frequency of ﬂt-3 738T/C poly-
morphism in dose-reduced group, but no signiﬁcant difference in ABCG2
421C/A polymorphism.Conclusion: This study showed a high incidence of sunitinib-induced
hematotoxicity in Japanese RCC patients, many of whom need dose
adjustment during the ﬁrst cycle. Further studies should verify whether
dose adjustment based on early-onset thrombocytopenia prolongs suni-
tinib treatment.
IPD06:
USE OF INTRAOPERATIVE STRAIN ELASTOGRAPHY OF SMALL RENAL
MASSES TO DIFFERENTIATE BETWEEN ANGIOMYOLIPOMA AND
RENAL CELL CARCINOMA
Shohei Fukuda, Toshihiro Kanda, Naotaka Fukui, Yukio
Kageyama. Department of Urology, Saitama Cancer Center, Saitama, Japan
Purpose: Elastography is a novel ultrasound modality that evaluates tissue
stiffness. This modality has been applied for the preoperative diagnosis of
breast, liver, prostate, kidney, and thyroid cancers. In this study we
assessed the diagnostic value of intraoperative elastography in patients
with renal tumors.
Materials and Methods: This prospective study included 46 patients
(mean age 62.4 years; range 38e85 years) with a renal tumor or tumors
who underwent partial or radical nephrectomy fromMay 2014 to February
2016. Strain elastography was performed intraoperatively and strain ratios
(tumor versus normal parenchyma) were evaluated before renal artery
dissection in 46 renal tumors (mean size 41.5 mm; range 9.0e127 mm).
Histology of the resected tumors revealed clear cell renal cell carcinoma
(RCC) in 32, chromophobe RCC in 3, papillary RCC in 1, multilocular cystic
RCC in 1, invasive urothelial carcinoma (UC) in 1, oncocytoma in 1, angio-
myolipoma (AML) in 6 and leiomyoma in 1.
Results: The median tumor diameters were 41 mm (range 12e80 mm) for
clear cell RCC, 25 mm (range 18e52 mm) for chromophobe RCC, 39 mm
for papillary RCC, 18 mm for multilocular cystic RCC, 66 mm for invasive
UC, 17mm for oncocytoma, 13.5 mm (range 9.0e127 mm) for AML, and
79 mm for leiomyoma. The median strain ratios were 1.67 (range
0.37e4.75) for clear cell RCC, 1.30 (range 0.81e2.52) for chromophobe
RCC, 4.11 for papillary RCC, 2.29 for multilocular cystic RCC, 6.00 for
invasive UC, 1.85 for oncocytoma, 1.13 (range 0.30e2.29) for AML, and 1.68
for leiomyoma. For tumors smaller than 40 mm, the median strain ratio
was signiﬁcantly higher in RCCs (clear cell, chromophobe, papillary, and
multilocular cystic; n¼20) compared with AMLs (n¼5) (2.09 [range
0.37e4.11] versus 1.11 [range 0.30e1.18]) (p¼0.010). According to receiver
operating characteristic curve analysis, the optimal cut-off value for dis-
tinguishing between RCCs and AML was 1.29, with a sensitivity and
speciﬁcity of 85% and 100%, respectively. The area under the curve was
0.880.
Conclusion: Intraoperative strain elastography may be a useful modality
for differentiating between AML and RCCs in patients with renal masses
smaller than 40 mm.
IPD07:
BIOPSY FOLLOW-UP IN PATIENTS WITH ATYPICAL SMALL ACINAR
PROLIFERATION AND PROSTATE INTRAEPITHELIAL NEOPLASM IN
PROSTATE BIOPSY
Sheng-Yung Tung, Chung-Hsin Chen, Huai-Chin Tai, Sho-Mon Wang, Kuo-
How Huang, Chao-Yuan Huang, Shih-Ping Liu, Yeong-Shiau
Pu. Department of Urology, National Taiwan University Hospital, Taipei,
Taiwan
Purpose: We investigated the prognosis and outcome of atypical small
acinar proliferation (ASAP) and extensive high grade prostate intra-
epithelial neoplasm (PIN) in prostate cancer detection in Taiwan.
Materials and Methods:We retrospectively reviewed our prostate biopsy
database containing data acquired over a 20-year period in National
Taiwan University Hospital. Data collection was done by chart review. We
analyzed patient in this study period with pathology reports including
atypical glands, atypical small acinar proliferation, prostatic intraepithelial
neoplasia after receiving prostate biopsy.
Results: A total of 66 patients were enrolled. 38 patients initially had
atypical glands/ atypical small acinar proliferation; 26 patients initially
had prostatic intraepithelial neoplasia; and 2 patient had atypical small
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patients in ASAP group were later diagnosed as prostate cancer, 6 (23.1%)
patients in PIN group were later diagnosed as prostate cancer, and 100%
patients in ASAP+PIN group were later diagnosed as prostate cancer.
Conclusion: Patients with a diagnosis of ASAP or extensive high grade PIN
during prostate biopsy had a higher chance of developing prostate cancer,
especially for patients with a simultaneous diagnosis of ASAP + PIN in the
same biopsy. These patients should receive second time biopsy during
follow up. Most cancer of the cancer in these patients could be detected
within twice re-biopsy.
IPD08:
NEW CIRCULATING TUMOR CELLS (CTCS) EVALUATION METHOD IN
PROSTATE CANCER
TakehikoNakasato 1,MichioNaoe 1, KazukoTujiyama1, YukiMatui 1, Kazuhiko
Oshinomi1, Jun Morita 1, Kohzo Fuji 1, Yoshio Ogawa M.D1, Masayuki
Ishige 2, Kousuke Osawa 2, Masaharu Matuzaki 2. 1Department of Urology,
Showa University School of Medicine, Tokyo, Japan; 2On-chip Biotechnologies
Co., Ltd., Japan
Purpose: AR-V7 is one of a splicing variant of the Androgen receptor (AR).
It cause castration resistant prostate cancer (CRPC).
Incontrast, CTCs is expected as a predictive factor for patient's prognosis
and as a biomarker of the disease.
CellSearch is the only FDA approval method as an evaluation of CTCs
ensuring the quantitative evaluation. This methodology is depending on
the expression of EpCAM and CK. However, the decrease expression of
EpCAM and CK caused by Epithelial-Mesenchymal Transition (EMT) can be
an obstacle to CTC detection.
In recent years, AdnaTest is used for the evaluation of CRPC. It captures CTC
depending on EpCAM and Her2 expression on cancer cells, then assess the
presence of AR-V7 mRNA. But, this method is semi-quantitative and also
depending on expression of EpCAM.
We consider it is important to know the number of ARV-7 positive cells
accurately. Because, CTCs of each prostate cancer patients are
heterogeneous.
The aim of our study is to establish a new method of improved detection
rate of EpCAM and CK-negative cells (i.e EMTcells), ensure the quantitative
evaluation and assess the number of AR-V7-positive cells.
Materials and Methods: LNcap was used as hormone sensitive prostate
cancer (HSPC) model, and Vcap, PC3 and Du145 were used as CRPC model.
Peripheral blood mononuclear cell (PBMC) and VMRC-RCW (Renal cell
carcinoma cell) were used as negative control.
CK and EpCAM antibodies were used as CTC-speciﬁc antibodies.PSA, PSMA
and AR-FL antibody were used as prostate-speciﬁc antibodies, cells which
show positivitiys for those antiodies within peripheral blood were
considered as CTCs.In addition, vimentin antibody was used for the pur-
pose of evaluating the EMT cells.
AR-V7 antibody was used as a biomarker for prostate cancer. On-chip sort
was used for quantitative assessment of CTCs.
Conclusion: Negativity of CK-Ab for LNCap and EpCAM-Ab for PC3 may
indicate that EMToccurs in LNCap and PC3. Positivity of PSMA-Ab, PSA-Ab
and AR-FL-Ab for LNCap indicates the possibility of improving the
detection rate of CTC. Positivity of AR-V7-Ab for Vcap and low positivity
for LNcap were likely to be the evaluation of new biomarkers in CTC
studies.
IPD09:
THE IMPACT OF TUMOR LOCATIONS ON LOCAL RECURRENCES IN
PROSTATE CANCER PATIENTS RECEIVING CRYOABLATION
Shih-Chun Hung, Chung-Hsin Chen, Yeong-Shiau Pu. Department of
Urology, National Taiwan University Hospital, National Taiwan University
College of Medicine, Taipei, Taiwan
Purpose: To evaluate the impact of tumor locations on local recurrences in
prostate cancer patient who received cryoablation
Materials and Methods: A total 255 patients with prostate cancer who
received primary cryoablation in National Taiwan University Hospital be-
tween January 2008 and December 2012 were enrolled. During follow-up,biochemical failure (Phoenix criteria) would trigger prostate biopsies.
Local recurrence refers to pathologically proven prostate cancer in prostate
and seminal vesicles. The prostate was deﬁned into eight areas: left lateral
(LL), left medial (LM), left apex (LA), right lateral (RL), right medial (RM),
right apex (RA), anterior and midline posterior (PM). The seminal vesicles
also deﬁned as one area each: left seminal vesicle (LSV), right seminal
vesicle (RSV). We analyzed the prostate cancer recurrence rate of each area
after primary cryoablation.
Results: A total of 46 (18.0%) patients had local recurrences during a me-
dian follow-up duration of 5 years. In the primary tumor areas, local
recurrence rates were 7.1% (RM), 3.4% (RA), 2.4% (RSV), 2.6% (LSV), 1.1%
(LM), 2.1% (LL), and 0 (RL, anterior, PM, LA). For the areas with negative
results for malignancy in pre-operative prostate biopsies, local recurrence
rates were 2.4% (RSV), 1.1% (RL) and 0 (other areas). For patients whose
anterior and PM areas were not routinely examed in pre-operative prostate
biopsy, local recurrence rates were 3.3% (anterior) and 1.7% (PM). Multi-
variate analysis revealed higher tumor stages, and tumor locations at RM,
and anterior areas were associated with higher risk of local recurrence.
Those patients with previously proved cancer distribution at the right
medial had highest recurrence rate at this area.
Conclusion: Limited to the nature of cryoablation and preservation of vital
organs nearby, tumor locations in prostate would interfere with the suc-
cessful rate of prostate cryoablation. To improve oncological outcomes,
detailed and accurate tumor locations is essential for prostate patients
who plan to receive cryoablation.
IPD10:
THE ONCOLOGICAL OUTCOMES AND SURVEILLANCE POLICY OF
TESTICULAR CANCER: 6-YEAR SINGLE CENTER EXPERIENCE IN TAIWAN
Yung-Ting Cheng, Kuo-How Huang, Yeong-Shiau Pu. Department of
Urology, National Taiwan University Hospital, Taiwan
Purpose: We investigated the treatment outcome of testicular cancer in
Taiwan, given globally rise in incidence in recent decades.
Materials and Methods: From February 2010 to October 2015, we retro-
spectively collected patients with the conﬁrmed diagnosis of testicular
cancer. Clinical data, pathological details and treatment outcomes were
analyzed by reviewing medical records.
Results: A total of 81 patients with testicular cancer were enrolled; 40
(49.4%) had seminoma and 41(50.6%) had non-seminoma germ cell cancer.
The median age was 51 years old in seminoma and 30 years old in non-
seminoma group. The median follow up period was 30 months (range 1 to
70).
The staging in seminoma group showed 36 (90%) stage I, 1 (2.5%) stage IS, 2
(5%) stage II and 1 (2.5%) stage III. The staging in non-seminoma group was
29 (70%) stage I, 4 (10%) stage IS, 3 (7%) stage II and 5 (12%) stage III.
Approximately 97% of patients (35/36) with stage I seminoma and 90% (26/
29) of patients with stage I non-seminoma accepted active surveillance.
The overall recurrence rates were 12.5 % in seminoma and 31.7% in non-
seminoma group. Only two patients in Non-seminoma group died of
cancer. The 5-year recurrence free survival was 94.2% in seminoma and
84.2% in non-seminoma group. Five year overall survival yielded favorable
results: 100% in seminoma and 94.2% in non-seminoma group.
Conclusion: Our study provided the latest evidence on oncological out-
comes of testicular cancer. Active Surveillance in stage I testicular cancer
yielded good prognosis and served as a treatment option.
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IPD11:
KETAMINE ABUSE AND LOWER URINARY TRACT SYMPTOMS: A SURVEY
FROM DRUG REHABILITATION CENTERS IN TAIWAN
Ching-Heng Yen, Sheng-Tang Wu, Tai-Lung Cha, En Meng. Divisions of
Urology, Department of Surgery, Tri-Service General Hospital, National
Defense Medical Center, Taipei, Taiwan
Purpose: Ketamine is the most commonly abused psychotropic substance
among youngsters in Taiwan. Long-term ketamine use can cause chronic
